The year is off to good start for drug specialist GW Pharmaceuticals (GWP). The group, which still has over £150m sitting on its balance sheet, remains focused on treatments for childhood epilepsy, cancer pain and schizophrenia.
IC TIP:
Buy
at
414p
In the next two months, four new trials of the company’s existing product Epidiolex will kick off. Initial data from at least one of these trials is due before the end of the year. The group is also hoping the drug will prove effective in treating additional forms of epilepsy and should have some early data in the coming months.
